JNJ Stock Trades Above Moving Averages as Innovative Medicine Segment Drives Growth
Johnson & Johnson's (JNJ) stock has been trading above both its 50-day and 200-day simple moving averages since mid-June, indicating a positive longer-term trend and strong buying interest.
The company's Innovative Medicine segment is the primary growth engine, with sales rising 6.2% on an organic basis in the first half of 2026 despite the loss of exclusivity (LOE) of the blockbuster drug Stelara.
New drugs like Darzalex, Erleada, and Tremfya contributed significantly to growth, while JNJ also expects continued above-market growth through the remainder of 2026 from its key products, including Darzalex, Tremfya, Spravato, Carvykti, and Erleada.
However, JNJ faces challenges, such as patent expirations on key products like Stelara, which could weigh on future revenue streams. The company also has approximately 76,000 lawsuits for its talc-based products, primarily baby powders.